{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:56:18Z","timestamp":1780588578460,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03172-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:25:46Z","timestamp":1756459546000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of reduced-dose versus full-dose DOACs in extended treatment of VTE: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"59","author":[{"given":"Abdur Rafay","family":"Bilal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahood Ahmed","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M Washaqul","family":"Arfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur Raheem","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sajid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hateem","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheer","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Haris","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Ahmed","family":"Waqas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"10294","key":"3172_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","volume":"398","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kahn SR, Rodger MA (2021) Venous thromboembolism. Lancet 398(10294):64\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(20)32658-1","journal-title":"Lancet"},{"key":"3172_CR2","unstructured":"CDC. Data and Statistics on Venous Thromboembolism. Venous Thromboembolism (Blood Clots). January 31 (2025) Accessed July 13, 2025. https:\/\/www.cdc.gov\/blood-clots\/data-research\/facts-stats\/index.html"},{"key":"3172_CR3","unstructured":"2019 (2025) ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) | European Heart Journal | Oxford Academic. Accessed July 13. https:\/\/academic.oup.com\/eurheartj\/article\/41\/4\/543\/5556136"},{"key":"3172_CR4","doi-asserted-by":"publisher","first-page":"l4363","DOI":"10.1136\/bmj.l4363","volume":"366","author":"F Khan","year":"2019","unstructured":"Khan F, Rahman A, Carrier M et al (2019) Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 366:l4363. https:\/\/doi.org\/10.1136\/bmj.l4363","journal-title":"BMJ"},{"issue":"2","key":"3172_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","volume":"166","author":"SM Stevens","year":"2024","unstructured":"Stevens SM, Woller SC, Kreuziger LB et al (2024) Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012\u20132021. Chest 166(2):388\u2013404. https:\/\/doi.org\/10.1016\/j.chest.2024.03.003","journal-title":"Chest"},{"issue":"8","key":"3172_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","volume":"368","author":"S Schulman","year":"2013","unstructured":"Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368(8):709\u2013718. https:\/\/doi.org\/10.1056\/NEJMoa1113697","journal-title":"N Engl J Med"},{"issue":"9","key":"3172_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"},{"issue":"15","key":"3172_CR8","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"null null","year":"2013","unstructured":"null null (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"issue":"13","key":"3172_CR9","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden A (2020) Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc 9(13):e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559","journal-title":"J Am Heart Assoc"},{"key":"3172_CR10","unstructured":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial - The Lancet. Accessed July 13 (2025) https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)02842-3\/fulltext"},{"issue":"7","key":"3172_CR11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jth.14156","volume":"16","author":"L Vasanthamohan","year":"2018","unstructured":"Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M (2018) Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16(7):1288\u20131295. https:\/\/doi.org\/10.1111\/jth.14156","journal-title":"J Thromb Haemost"},{"key":"3172_CR12","doi-asserted-by":"crossref","unstructured":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration | The BMJ. Accessed July 13 (2025) https:\/\/www.bmj.com\/content\/339\/bmj.b2700","DOI":"10.1136\/bmj.b2700"},{"key":"3172_CR13","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions | Wiley Online Books. Accessed July 13 (2025) https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781119536604"},{"key":"3172_CR14","unstructured":"RoB 2: a revised tool for assessing risk of bias in randomised trials | The BMJ. Accessed July 13 (2025) https:\/\/www.bmj.com\/content\/366\/bmj.l4898"},{"issue":"7414","key":"3172_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"3172_CR16","unstructured":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial - Journal of Thrombosis and Haemostasis. Accessed July 13 (2025) https:\/\/www.jthjournal.org\/article\/S1538-7836(24)00169-7\/fulltext"},{"key":"3172_CR17","doi-asserted-by":"publisher","unstructured":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism | New England Journal of Medicine. Accessed July 13 (2025) https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1700518","DOI":"10.1056\/NEJMoa1700518"},{"key":"3172_CR18","doi-asserted-by":"publisher","unstructured":"Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | New England Journal of Medicine. Accessed July 13 (2025) https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2416112","DOI":"10.1056\/NEJMoa2416112"},{"key":"3172_CR19","unstructured":"Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review - PubMed. Accessed August 7 (2025) https:\/\/pubmed.ncbi.nlm.nih.gov\/35648414\/"},{"issue":"2","key":"3172_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","volume":"22","author":"E Donnellan","year":"2017","unstructured":"Donnellan E, Khorana AA (2017) Cancer and venous thromboembolic disease: a review. Oncologist 22(2):199\u2013207. https:\/\/doi.org\/10.1634\/theoncologist.2016-0214","journal-title":"Oncologist"},{"key":"3172_CR21","doi-asserted-by":"publisher","unstructured":"Cancer-associated venous thromboembolism: a comprehensive review | Thrombosis Journal | Full Text. Accessed July 13 (2025) https:\/\/thrombosisjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12959-025-00719-7","DOI":"10.1186\/s12959-025-00719-7"},{"issue":"2","key":"3172_CR22","doi-asserted-by":"publisher","first-page":"26573","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2018","unstructured":"Johnstone C, Rich SE (2018) Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 7(2):26573\u201326273. https:\/\/doi.org\/10.21037\/apm.2017.11.01","journal-title":"Ann Palliat Med"},{"issue":"11","key":"3172_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40265-013-0082-7","volume":"73","author":"P Sardar","year":"2013","unstructured":"Sardar P, Chatterjee S, Mukherjee D (2013) Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. Drugs 73(11):1171\u20131182. https:\/\/doi.org\/10.1007\/s40265-013-0082-7","journal-title":"Drugs"},{"issue":"5","key":"3172_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/life12050705","volume":"12","author":"S Reda","year":"2022","unstructured":"Reda S, Rudde E, M\u00fcller J et al (2022) Variation in plasma levels of Apixaban and Rivaroxaban in clinical routine treatment of venous thromboembolism. Life (Basel) 12(5):705. https:\/\/doi.org\/10.3390\/life12050705","journal-title":"Life (Basel)"},{"key":"3172_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/CPAA.S61131","volume":"6","author":"C Frost","year":"2014","unstructured":"Frost C, Song Y, Barrett YC et al (2014) A randomized direct comparison of the pharmacokinetics and pharmacodynamics of Apixaban and Rivaroxaban. Clin Pharmacol 6:179\u2013187. https:\/\/doi.org\/10.2147\/CPAA.S61131","journal-title":"Clin Pharmacol"},{"issue":"4","key":"3172_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","volume":"5","author":"IA N\u00e6ss","year":"2007","unstructured":"N\u00e6ss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstr\u00f8m J (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5(4):692\u2013699. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02450.x","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3172_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB Abdol Razak","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P (2018) Cancer-Associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 10(10):380. https:\/\/doi.org\/10.3390\/cancers10100380","journal-title":"Cancers (Basel)"},{"key":"3172_CR28","doi-asserted-by":"publisher","unstructured":"Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association. Accessed July 13 (2025) https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/JAHA.120.017559","DOI":"10.1161\/JAHA.120.017559"},{"key":"3172_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100216","volume":"23","author":"CT Ruff","year":"2022","unstructured":"Ruff CT (2022) The importance of dosing frequency on the safety of DOACs. American Heart Journal Plus: Cardiology Research and Practice 23:100216. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100216","journal-title":"American Heart Journal Plus: Cardiology Research and Practice"},{"key":"3172_CR30","unstructured":"Endothelial cell control of thrombosis | BMC Cardiovascular Disorders | Full Text. Accessed July 13 (2025) https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-015-0124-z"},{"key":"3172_CR31","unstructured":"Frontiers | Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation. Accessed July 13 (2025) https:\/\/www.frontiersin.org\/journals\/cardiovascular-medicine\/articles\/10.3389\/fcvm.2022.864735\/full"},{"issue":"7","key":"3172_CR32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/jth.14837","volume":"18","author":"J Catella","year":"2020","unstructured":"Catella J, Bertoletti L, Mismetti P et al (2020) Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. J Thromb Haemost 18(7):1728\u20131737. https:\/\/doi.org\/10.1111\/jth.14837","journal-title":"J Thromb Haemost"},{"key":"3172_CR33","doi-asserted-by":"crossref","unstructured":"Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide. Accessed July 13 (2025) https:\/\/www.mdpi.com\/2077-0383\/14\/9\/2914","DOI":"10.3390\/jcm14092914"},{"key":"3172_CR34","unstructured":"Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism | Cardiology | JAMA Network Open | JAMA Network. Accessed July 13 (2025) https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808360"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03172-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:41:45Z","timestamp":1770644505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3172"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03172-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"15 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}]}}